INT99911

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2001
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 3.81
Pain Relevance 3.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (MTX1)
Anatomy Link Frequency
goblet cells 1
MTX1 (Homo sapiens)
Pain Link Frequency Relevance Heat
methotrexate 114 100.00 Very High Very High Very High
Arthritis 56 99.84 Very High Very High Very High
psoriasis 60 99.12 Very High Very High Very High
rheumatoid arthritis 160 98.72 Very High Very High Very High
cINOD 4 97.72 Very High Very High Very High
adenocard 3 96.68 Very High Very High Very High
Adalimumab 240 96.56 Very High Very High Very High
Inflammation 30 95.68 Very High Very High Very High
spinal inflammation 25 90.48 High High
Sumatriptan 1 83.68 Quite High
Disease Link Frequency Relevance Heat
Adenocarcinoma 1 100.00 Very High Very High Very High
Seronegative Spondarthritis 45 99.84 Very High Very High Very High
Psoriasis 69 99.12 Very High Very High Very High
Rheumatoid Arthritis 162 98.72 Very High Very High Very High
INFLAMMATION 37 97.24 Very High Very High Very High
Low Back Pain 29 90.48 High High
Disease 63 84.04 Quite High
Adverse Drug Reaction 1 77.72 Quite High
Infection 39 74.60 Quite High
Hepatitis 3 74.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The similarity of both the diffusion coefficients and permeability values obtained for a range of hydrophilic and lipophilic compounds in the two models indicates that the mucus layer secreted by the human adenocarcinoma HT29-MTX goblet cells does not constitute a diffusion barrier to such compounds.
Localization (secreted) of HT29-MTX in goblet cells associated with adenocarcinoma
1) Confidence 0.45 Published 2001 Journal J Pharm Sci Section Abstract Doc Link 11745719 Disease Relevance 0.10 Pain Relevance 0.08
Patients (n=313) were stratified according to MTX use (yes or no) and extent of psoriasis involvement (?
Neg (no) Localization (yes) of MTX associated with psoriasis and methotrexate
2) Confidence 0.34 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936294 Disease Relevance 1.22 Pain Relevance 1.17
Polyglutamation of MTX enhances the intracellular retention of MTX and promotes the inhibition of de novo purine synthesis along with the buildup of adenosine, a potent anti-inflammatory agent [56].
Localization (retention) of MTX associated with adenocard, inflammation and methotrexate
3) Confidence 0.34 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691664 Disease Relevance 0.65 Pain Relevance 0.85
The use of MTX in PsA is facultative, and, in RA patients not taking concomitant MTX, the dosing frequency can be increased to 40 mg every week to obtain additional benefit.
Localization (use) of MTX associated with rheumatoid arthritis, methotrexate and arthritis
4) Confidence 0.15 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721299 Disease Relevance 0.89 Pain Relevance 0.92
Simultaneous administration of MTX is not mandatory, since clinical trials conducted in Japan were performed with monotherapy.
Localization (administration) of MTX associated with methotrexate
5) Confidence 0.09 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2720589 Disease Relevance 0.94 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox